388 related articles for article (PubMed ID: 25589621)
1. Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.
Yaeger R; Cercek A; O'Reilly EM; Reidy DL; Kemeny N; Wolinsky T; Capanu M; Gollub MJ; Rosen N; Berger MF; Lacouture ME; Vakiani E; Saltz LB
Clin Cancer Res; 2015 Mar; 21(6):1313-20. PubMed ID: 25589621
[TBL] [Abstract][Full Text] [Related]
2. Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.
Hong DS; Morris VK; El Osta B; Sorokin AV; Janku F; Fu S; Overman MJ; Piha-Paul S; Subbiah V; Kee B; Tsimberidou AM; Fogelman D; Bellido J; Shureiqi I; Huang H; Atkins J; Tarcic G; Sommer N; Lanman R; Meric-Bernstam F; Kopetz S
Cancer Discov; 2016 Dec; 6(12):1352-1365. PubMed ID: 27729313
[TBL] [Abstract][Full Text] [Related]
3. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.
Kopetz S; Desai J; Chan E; Hecht JR; O'Dwyer PJ; Maru D; Morris V; Janku F; Dasari A; Chung W; Issa JP; Gibbs P; James B; Powis G; Nolop KB; Bhattacharya S; Saltz L
J Clin Oncol; 2015 Dec; 33(34):4032-8. PubMed ID: 26460303
[TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
5. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.
Di Nicolantonio F; Martini M; Molinari F; Sartore-Bianchi A; Arena S; Saletti P; De Dosso S; Mazzucchelli L; Frattini M; Siena S; Bardelli A
J Clin Oncol; 2008 Dec; 26(35):5705-12. PubMed ID: 19001320
[TBL] [Abstract][Full Text] [Related]
6. Predictive and prognostic factors in the complex treatment of patients with colorectal cancer.
László L
Magy Onkol; 2010 Dec; 54(4):383-94. PubMed ID: 21163770
[TBL] [Abstract][Full Text] [Related]
7. MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF-Mutated Colorectal Cancer.
Pietrantonio F; Oddo D; Gloghini A; Valtorta E; Berenato R; Barault L; Caporale M; Busico A; Morano F; Gualeni AV; Alessi A; Siravegna G; Perrone F; Di Bartolomeo M; Bardelli A; de Braud F; Di Nicolantonio F
Cancer Discov; 2016 Sep; 6(9):963-71. PubMed ID: 27325282
[TBL] [Abstract][Full Text] [Related]
8. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
[TBL] [Abstract][Full Text] [Related]
9. RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer-Response.
Yaeger R; Saltz LB
Clin Cancer Res; 2015 May; 21(9):2188. PubMed ID: 25934891
[No Abstract] [Full Text] [Related]
10. Single-Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild-Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope.
Pietrantonio F; Cremolini C; Aprile G; Lonardi S; Orlandi A; Mennitto A; Berenato R; Antoniotti C; Casagrande M; Marsico V; Marmorino F; Cardellino GG; Bergamo F; Tomasello G; Formica V; Longarini R; Giommoni E; Caporale M; Di Bartolomeo M; Loupakis F; de Braud F
Oncologist; 2015 Nov; 20(11):1261-5. PubMed ID: 26446234
[TBL] [Abstract][Full Text] [Related]
11. RAF plus EGFR Inhibition for BRAF-Mutant Metastatic Colorectal Cancer-Letter.
Sorscher S
Clin Cancer Res; 2015 May; 21(9):2187. PubMed ID: 25934890
[No Abstract] [Full Text] [Related]
12. A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic
van Geel RMJM; Tabernero J; Elez E; Bendell JC; Spreafico A; Schuler M; Yoshino T; Delord JP; Yamada Y; Lolkema MP; Faris JE; Eskens FALM; Sharma S; Yaeger R; Lenz HJ; Wainberg ZA; Avsar E; Chatterjee A; Jaeger S; Tan E; Maharry K; Demuth T; Schellens JHM
Cancer Discov; 2017 Jun; 7(6):610-619. PubMed ID: 28363909
[TBL] [Abstract][Full Text] [Related]
13. Vemurafenib and panitumumab combination tailored therapy in BRAF-mutated metastatic colorectal cancer: a case report.
Capalbo C; Marchetti P; Coppa A; Calogero A; Anastasi E; Buffone A; Belardinilli F; Gulino M; Frati P; Catalano C; Cortesi E; Giannini G; Gulino A
Cancer Biol Ther; 2014 Jul; 15(7):826-31. PubMed ID: 24755613
[TBL] [Abstract][Full Text] [Related]
14. Cetuximab plus FOLFOX-4 in untreated patients with advanced colorectal cancer: a Gruppo Oncologico dell'Italia Meridionale Multicenter phase II study.
Colucci G; Giuliani F; Garufi C; Mattioli R; Manzione L; Russo A; Lopez M; Parrella P; Tommasi S; Copetti M; Daniele B; Pisconti S; Tuveri G; Silvestris N; Maiello E
Oncology; 2010; 79(5-6):415-22. PubMed ID: 21474966
[TBL] [Abstract][Full Text] [Related]
15. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA
Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344
[TBL] [Abstract][Full Text] [Related]
16. Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with
Masuishi T; Taniguchi H; Kotani D; Bando H; Komatsu Y; Shinozaki E; Nakajima TE; Satoh T; Nishina T; Esaki T; Wakabayashi M; Nomura S; Takahashi K; Ono H; Hirano N; Fujishiro N; Fuse N; Sato A; Ohtsu A; Yoshino T
ESMO Open; 2019; 4(6):e000590. PubMed ID: 31798981
[TBL] [Abstract][Full Text] [Related]
17. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis.
Pietrantonio F; Petrelli F; Coinu A; Di Bartolomeo M; Borgonovo K; Maggi C; Cabiddu M; Iacovelli R; Bossi I; Lonati V; Ghilardi M; de Braud F; Barni S
Eur J Cancer; 2015 Mar; 51(5):587-94. PubMed ID: 25673558
[TBL] [Abstract][Full Text] [Related]
18. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer.
Loupakis F; Cremolini C; Salvatore L; Masi G; Sensi E; Schirripa M; Michelucci A; Pfanner E; Brunetti I; Lupi C; Antoniotti C; Bergamo F; Lonardi S; Zagonel V; Simi P; Fontanini G; Falcone A
Eur J Cancer; 2014 Jan; 50(1):57-63. PubMed ID: 24138831
[TBL] [Abstract][Full Text] [Related]
19. B-type proto-oncogene-mutated tumors of colon cancer: promising therapeutic approaches.
Temraz S; Alameddine R; Shamseddine A
Curr Opin Oncol; 2015 May; 27(3):276-81. PubMed ID: 25774859
[TBL] [Abstract][Full Text] [Related]
20. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer.
Douillard JY; Oliner KS; Siena S; Tabernero J; Burkes R; Barugel M; Humblet Y; Bodoky G; Cunningham D; Jassem J; Rivera F; Kocákova I; Ruff P; Błasińska-Morawiec M; Šmakal M; Canon JL; Rother M; Williams R; Rong A; Wiezorek J; Sidhu R; Patterson SD
N Engl J Med; 2013 Sep; 369(11):1023-34. PubMed ID: 24024839
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
